New drug combo aims to protect kidneys in heart patients
NCT ID NCT07304817
First seen Jan 11, 2026 · Last updated May 14, 2026 · Updated 17 times
Summary
This study compares two drugs, vicadrostat and spironolactone, both given with empagliflozin, to see how they affect kidney function and protein levels in blood and urine. About 100 adults with chronic kidney disease and heart disease or heart failure will take one of the two combinations daily for 26 weeks. The goal is to understand which drug works better for the kidneys and why.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Delphinium
RECRUITINGGroningen, Provincie Groningen, 9713GZ, Netherlands
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University Medical Center Groningen
RECRUITINGGroningen, Provincie Groningen, 9713GZ, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.